The Expiry of Humira(®) Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures

Background: From October 2018, adalimumab biosimilars could enter the European market. However, in some countries, such as Netherlands, high discounts reported for the originator product may have influenced biosimilar entry. Objectives: The aim of this paper is to provide a European overview of (lis...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Front Pharmacol
Prif Awduron: Moorkens, Evelien, Godman, Brian, Huys, Isabelle, Hoxha, Iris, Malaj, Admir, Keuerleber, Simon, Stockinger, Silvia, Mörtenhuber, Sarah, Dimitrova, Maria, Tachkov, Konstantin, Vončina, Luka, Palčevski, Vera Vlahović, Achniotou, Gnosia, Slabý, Juraj, Popelková, Leona, Kohoutová, Kateřina, Bartels, Dorthe, Laius, Ott, Martikainen, Jaana E., Selke, Gisbert W., Kourafalos, Vasileios, Magnússon, Einar, Einarsdóttir, Rannveig, Adams, Roisín, Joppi, Roberta, Allocati, Eleonora, Jakupi, Arianit, Viksna, Anita, Greičiūtė-Kuprijanov, Ieva, Vella Bonanno, Patricia, Suttorp, Vincent, Melien, Øyvind, Plisko, Robert, Mardare, Ileana, Meshkov, Dmitry, Novakovic, Tanja, Fürst, Jurij, Zara, Corinne, Marković-Peković, Vanda, Grubiša, Nataša, Befrits, Gustaf, Puckett, Robert, Vulto, Arnold G.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Frontiers Media S.A. 2021
Pynciau:
Pharmacology
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7839249/
https://ncbi.nlm.nih.gov/pubmed/33519450
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2020.591134
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg